Home » Doctors » Drugs » Currently Reading:

Boosting Medical Students’ Training in Drug Abuse

November 7, 2009 Doctors, Drugs No Comments

By Shirley S. Wang

Boosting Medical Students’ Training in Drug AbuseThere’s lot of action these days aimed at curbing the abuse of prescription drugs. The FDA is working on a plan to make it harder for people to get access to unauthorized prescription painkillers, pain specialists have come out with guidelines to help doctors manage pain-drug-abusing patients and drug companies have been developing abuse-resistant drugs.

Today, the National Institute on Drug Abuse jumped into the fray, announcing new teaching tools designed to help doctors-in-training — medical students and residents — learn about assessing and treating patients with abuse problems, including tobacco, prescription drugs and illicit substances. The materials mark the “first step” that NIDA has taken into trying to educate physicians about drug abuse, according to Gayathri Dowling, NIDA’s deputy chief of science policy.

Currently, the amount of education students receive in medical school about drug abuse varies a lot, and many docs aren’t sufficiently trained. These new materials, based on case studies and designed to be incorporated into the current curriculum, will present “real-world scenarios that medical students can grapple with,” Dowling told the Health Blog. For instance, methamphetamine users can get chest pain, and asking about drug use in that situation could affect how a doctor decides to treat the patient.

NIDA is also “exploring” whether to develop these materials into a continuing medical education course that licensed doctors could take to accrue the credits they need to continue practicing, says Dowling. The hope is that by getting to physicians early, doctors will incorporate the assessment and treatment of drug abuse into their regular practice, says Dowling.

Photo: iStockphoto

Comment on this Article:







Partner links

Advertising

Drugs

South Korean FDA Probes Roche for Aiding Tamiflu Stockpiling

November 8, 2009

By Shirley S. Wang
Should companies be allowed to buy large quantities of medicine like Tamiflu to have on hand in case their employees develop the H1N1 flu virus? Not according to the law in South Korea, where it’s illegal for non-medical professionals to purchase big lots of drugs. Punishment is up to five years in [...]

Boosting Medical Students’ Training in Drug Abuse

November 7, 2009

By Shirley S. Wang
There’s lot of action these days aimed at curbing the abuse of prescription drugs. The FDA is working on a plan to make it harder for people to get access to unauthorized prescription painkillers, pain specialists have come out with guidelines to help doctors manage pain-drug-abusing patients and drug companies have been [...]

What Will Pfizer’s R&D Look Like a Year from Now?

October 21, 2009

By Jonathan D. Rockoff
Pfizer’s huge R&D shop is even bigger now that the company has swallowed Wyeth. To get a sense of the changes that could be in store, the Health Blog spoke today with the company’s two top R&D execs — Martin Mackay, a Pfizer veteran who will lead small-molecule work, and Mikael Dolsten, [...]

See Your Doctor: The Dawn of Consumer Drug Ads

October 13, 2009

By Jacob Goldstein
For a look back at a key breakthrough in the history of the pharmaceutical industry, we turn now to Joe Davis, a retired ad guy who lives in Vermont.
Back in the mid-1980s, Davis came up with an idea: Run a TV ad for Seldane, the allergy medicine, but don’t say the drug’s name. [...]

Why Other Drugmakers Want to Be More Like J&J

October 12, 2009

By Jacob Goldstein
Johnson & Johnson’s third-quarter earnings, out today, provide the latest reminder of why other drugmakers want to be more like J&J.
In a nutshell: It’s a tough time to be in the prescription drug business, what with stiff competition from generics manufacturers and payers pushing for lower costs on branded drugs. So it’s nice [...]

Related Links

Research

What Will Pfizer’s R&D Look Like a Year from Now?

October 21, 2009

By Jonathan D. Rockoff
Pfizer’s huge R&D shop is even bigger now that the company has swallowed Wyeth. To get a sense of the changes that could be in store, the Health Blog spoke today with the company’s two top R&D execs — Martin Mackay, a Pfizer veteran who will lead small-molecule work, and Mikael Dolsten, [...]

Are Mammograms and PSA Tests Overrated?

October 21, 2009

By Jacob Goldstein
Catch cancers early and treat them before they become deadly. That’s the idea behind cancer screening, and that’s clearly how it works with pap smears for cervical cancer and colonoscopy for colon cancer.
But in some cases screening can lead to aggressive treatment of slow-growing tumors that would never have caused a problem [...]

The Problem With Ranking Countries’ Health-Care Systems

October 20, 2009

By Jacob Goldstein
The oft-cited WHO ranking that said the U.S. has the 37th best health-care system in the world is dated and had problems even when it was new, WSJ stats maven Carl Bialik writes in his column today.
The ranking was published in 2000, and came up against a major problem: Good data weren’t available [...]